Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$1.11M
EBITDA Margin
-6.76%
TTM Avg
-0.42%
3Y Avg
7.09%
5Y Avg
7.09%
Market Cap
$1.13M
EBITDA Margin
-17.60%
TTM Avg
-16.25%
3Y Avg
-23.94%
5Y Avg
-32.10%
Market Cap
$1.02M
EBITDA Margin
-182712.72%
TTM Avg
-182712.72%
3Y Avg
-182712.72%
5Y Avg
-182712.72%
Market Cap
$901902.00
EBITDA Margin
1710.10%
TTM Avg
8440.35%
3Y Avg
4905.18%
5Y Avg
4832.78%
Market Cap
$858572.00
EBITDA Margin
-11.42%
TTM Avg
-13.72%
3Y Avg
-61.43%
5Y Avg
-349.42%
Market Cap
$848052.00
EBITDA Margin
-3618.46%
TTM Avg
-3618.46%
3Y Avg
-3618.46%
5Y Avg
-3618.46%
Market Cap
$850879.00
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clearmind Medicine Inc. (CMND) | $1.09M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | -6.76% | -0.42% | 7.09% | 7.09% |
| IM Cannabis Corp. (IMCC)vs › | $1.13M | -17.60% | -16.25% | -23.94% | -32.10% |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | -182712.72% | -182712.72% | -182712.72% | -182712.72% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.15M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | 1710.10% | 8440.35% | 4905.18% | 4832.78% |
| Sunshine Biopharma, Inc. (SBFM)vs › | $858572.00 | -11.42% | -13.72% | -61.43% | -349.42% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $848052.00 | -3618.46% | -3618.46% | -3618.46% | -3618.46% |
| Bone Biologics Corporation (BBLG)vs › | $850879.00 | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.35M | N/A | N/A | N/A | N/A |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
